A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Healthy Subjects Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of TLC-2716 in Healthy Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05483998
• Other study ID #: 2716-CL-101
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 9, 2022
• Est. completion date: May 2023

Study information

• Verified date: April 2023
• Source: OrsoBio, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TLC-2716 after single- and multiple-ascending doses in healthy subjects.

Description:

This study is a randomized, placebo-controlled, sponsor-unblinded, and comprised of three parts: Part A (single-ascending dose), Part B (multiple-ascending dose), and Part C (adaptive single- and/or multiple-ascending dose).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: May 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Non-smoking, healthy male or female subject between 18 and 55 years of age, inclusive
• Body mass index from 19 to 35 kg/m2, inclusive
• Estimated glomerular filtration rate = 80 mL/min
• Normal liver biochemistry tests
• Screening laboratory evaluations (hematology, chemistry, and urinalysis) must fall within the normal range of the local laboratory's reference ranges unless the results have been determined by the investigator to have no clinical significance
• Subject must have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that are considered clinically insignificant by the investigator
• Females of childbearing potential must have a negative pregnancy test at Screening and clinic admission
• Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception
• Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs

Exclusion Criteria:

• Pregnant or lactating subjects
• Subjects with triglycerides = 500 mg/dL
• Subjects with low-density lipoprotein = 190 mg/dL
• Subjects who have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with the subject's treatment, assessment, or compliance with the protocol
• Subjects who have received any investigational compound within 30 days or 5 half-lives, whichever is longer, prior to study drug dosing
• Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
• Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
• A positive test result for human immunodeficiency virus (HIV-1) antibody, hepatitis B (HBV) surface antigen, or hepatitis C (HCV) antibody
• Subjects who have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins, acetaminophen (paracetamol), ibuprofen, and/or hormonal contraceptive medications
• Subjects who have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to Screening or expected to receive these agents during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
• Medical history of serious skin disease in the opinion of the investigator, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria
• Medical history of drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
• Presence or history of cardiovascular disease, including significant cardiovascular disease (including a history of myocardial infarction based on ECG and/or clinical history), history of cardiac conduction abnormalities (including any history of ventricular tachycardia), congestive heart failure, cardiomyopathy with left ventricular ejection fraction < 40%, a family history of Long QT Syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years
• Syncope, palpitations, or unexplained dizziness
• Implanted defibrillator or pacemaker
• Medical history of liver disease, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency)
• Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions
• History of medical or surgical treatment that permanently alters intestinal absorption (e.g., gastric or intestinal surgery)
• Subjects who have received vaccination for COVID-19 within 14 days of Admission Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• TLC-2716
TLC-2716

Other:
• Placebo
Placebo to match

Locations

Country	Name	City	State
New Zealand	OrsoBio Research Site	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
OrsoBio, Inc

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with treatment-emergent adverse events (TEAEs) in single ascending dose (SAD) compared to placebo	TEAEs are AEs that occur following the start of treatment or AEs increasing in severity during treatment.	Up to Day 15
Primary	Number of subjects with clinically significant change from Baseline in vital signs in SAD	Vital signs include blood pressure, heart rate, respiratory rate, and temperature.	Day 1-Day 4, and Follow-up (after 11 days)
Primary	Number of subjects with laboratory abnormalities in SAD	Hematology and serum chemistry.	Up to 15 days
Primary	Number of subjects with electrocardiogram (ECG) abnormalities in SAD	12-lead ECG.	Up to 15 days
Primary	Number of subjects with TEAEs in multiple ascending dose (MAD) compared to placebo	TEAEs are AEs that occur following the start of treatment or AEs increasing in severity during treatment.	Up to Day 28
Primary	Number of subjects with clinically significant change from Baseline in vital signs in MAD	Vital signs include blood pressure, heart rate, respiratory rate, and temperature.	Day 1 - Day 3, Day 5, Day 7, Day 10, Day 14, Day 17, and Follow-up (after 11 days)
Primary	Number of subjects with laboratory abnormalities in MAD	Hematology and serum chemistry.	Up to 28 days
Primary	Number of subjects with ECG abnormalities in MAD	12-lead ECG	Up to 28 days
Secondary	Plasma concentration of each dose of study drug to determine AUClast in SAD	AUClast is defined as the concentration of drug from time zero to the last observable concentration.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine AUCinf in SAD	AUCinf is defined as the concentration of drug extrapolated to infinite time.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine %AUCexp in SAD	%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine CL/F in SAD	CL/F is defined as the apparent oral clearance following administration of the drug.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine Cmax in SAD	Cmax is defined as the maximum concentration of drug.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine Tmax in SAD	Tmax is defined as the time (observed time point) of Cmax.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine Clast in SAD	Clast is defined as the last observable concentration of drug.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine Tlast in SAD	Tlast is defined as the time (observed time point) of Clast.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine t1/2 in SAD	t1/2 is defined as the estimate of the terminal elimination half-life of the drug.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine ?z in SAD	?z is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.	Day 1: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 48, and 72 hours post-dose
Secondary	Plasma concentration of each dose of study drug to determine AUClast in MAD	AUClast is defined as the concentration of drug from time zero to the last observable concentration.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine AUCtau in MAD	AUCtau is the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine Ctau in MAD	Ctau is defined as the observed drug concentration at the end of the dosing interval.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine CLss/F in MAD	CLss/F is the total body clearance for extravascular administration divided by the fraction of dose absorbed.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine Cmax in MAD	Cmax is defined as the maximum concentration of drug.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine Tmax in MAD	Tmax is defined as the time (observed time point) of Cmax.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine Clast in MAD	Clast is defined as the last observable concentration of drug.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine Tlast in MAD	Tlast is defined as the time (observed time point) of Clast.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine t1/2 in MAD	t1/2 is defined as the estimate of the terminal elimination half-life of the drug.	Day 1, Day 3, Day 7, Day 14
Secondary	Plasma concentration of each dose of study drug to determine ?z in MAD	?z is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.	Day 1, Day 3, Day 7, Day 14